- Molecular NameFenoldopam
- SynonymFenodopam mesylate; Fenoldopam mesylate; Fenoldopamum [Latin]
- Weight305.761
- Drugbank_IDDB00800
- ACS_NO67227-56-9
- Show 2D model
- LogP (experiment)2.39
- LogP (predicted, AB/LogP v2.0)2.29
- pkaN/A
- LogD (pH=7, predicted)-0.26
- Solubility (experiment)4 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.84
- LogSw (predicted, AB/LogsW2.0)2.22
- Sw (mg/ml) (predicted, ACD/Labs)3.63
- No.of HBond Donors4
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA72.72
- StatusFDA approved
- AdministrationN/A
- PharmacologyA synthetic benzazepine derivative drug that acts as a selective peripheral dopamine D1 receptor weak partial agonist.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability6.0
- Protein binding88.0
- Volume of distribution (VD)0.23 L/kg (0.025 μg/kg body weight/min dose) to 0.66 L/kg (0.25 and 0.5 μg/kg body weight/min).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP not involved). Fenoldopam is extensively metabolised by conjugation: glucuronidation, sulfation and methylation. Metabolites include fenoldopam 7-sulfate and 8-sulfate
- Half life5~10 min
- ExcretionMetabolites include fenoldopam 7-sulfate and 8-sulfate which are excreted predominantly in urine (90%) and faeces (10%). Approx. 4% of a dose is excreted unchanged in urine. Less than 0.005% of the drug crosses the blood–brain barrier.
- Urinary ExcretionN/A
- Clerance1.49 L/h/kg (0.025 μg/kg body weight/min dose) to 2.29 L/h/kg (0.5 μg/kg body weight/min dose).
- ToxicityReported to be 6 times as potent as dopamine in causing vasodilation.
- LD50 (rat)N/A
- LD50 (mouse)N/A